SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement
Background: Polymorphisms in VKORC1 (vitamin K epoxide reductase complex subunit 1) and CYP2C9 (cytochrome P450 2C9) genes are considered the major genetic factors modulating warfarin dose requirement. As a result, a rapid and economic method for genotyping patients for predicting warfarin dose coul...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Walter de Gruyter ; 2008 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
©2009 by Walter de Gruyter Berlin New York |
|---|---|
| Umfang: |
6 |
| Reproduktion: |
Walter de Gruyter Online Zeitschriften |
|---|---|
| Übergeordnetes Werk: |
Enthalten in: Clinical chemistry and laboratory medicine - Berlin [u.a.] : De Gruyter, 1998, 47(2008), 1 vom: 31. Dez., Seite 26-31 |
| Übergeordnetes Werk: |
volume:47 ; year:2008 ; number:1 ; day:31 ; month:12 ; pages:26-31 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1515/CCLM.2009.008 |
|---|
| Katalog-ID: |
NLEJ246726105 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ246726105 | ||
| 003 | DE-627 | ||
| 005 | 20230506100904.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220814s2008 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1515/CCLM.2009.008 |2 doi | |
| 028 | 5 | 2 | |a artikel_Grundlieferung.pp |
| 035 | |a (DE-627)NLEJ246726105 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 245 | 1 | 0 | |a SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement |
| 264 | 1 | |b Walter de Gruyter |c 2008 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a ©2009 by Walter de Gruyter Berlin New York | ||
| 520 | |a Background: Polymorphisms in VKORC1 (vitamin K epoxide reductase complex subunit 1) and CYP2C9 (cytochrome P450 2C9) genes are considered the major genetic factors modulating warfarin dose requirement. As a result, a rapid and economic method for genotyping patients for predicting warfarin dose could be useful in clinical applications. Methods: In this study, we developed and validated a melting temperature (Tm)-shift genotyping assay for detection of VKORC1 C1173T and CYP2C9 A1075C polymorphisms by using SYBR Green-based multiplex allele-specific PCR and consequent melting curve analysis. In this Tm-shift genotyping assay, a GC-tail was incorporated into one of the two allele-specific primers to increase the melting temperature of PCR product, such that both alleles can be differentially detected simultaneously at their respective melting curve patterns. In total, 100 randomly selected samples of both VKORC1 and CYP2C9 genes from each genotype group determined by melting curve were validated by direct DNA sequencing and denaturing high-performance liquid chromatography (DHPLC) analysis. Results: There was 100% concordance between the results of DNA sequencing and Tm-shift genotyping, and 99% concordance between the results of DHPLC assay and Tm-shift genotyping. Conclusions: This allele-specific PCR assay is convenient, inexpensive and will be useful for VKORC1 and CYP2C9 genotyping in a clinic laboratory. Clin Chem Lab Med 2009;47:26–31. | ||
| 533 | |f Walter de Gruyter Online Zeitschriften | ||
| 650 | 4 | |a CYP2C9 | |
| 650 | 4 | |a real-time PCR | |
| 650 | 4 | |a Tm-shift genotyping | |
| 650 | 4 | |a VKORC1 | |
| 650 | 4 | |a warfarin | |
| 700 | 1 | |a Huang, Sheng-Wen |4 oth | |
| 700 | 1 | |a Li, Qiang |4 oth | |
| 700 | 1 | |a Zhu, Sheng-Yuan |4 oth | |
| 700 | 1 | |a Li, Liang |4 oth | |
| 700 | 1 | |a Xiong, Fu |4 oth | |
| 700 | 1 | |a Jia, Yan-Kai |4 oth | |
| 700 | 1 | |a Xu, Xiang-Min |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d Berlin [u.a.] : De Gruyter, 1998 |g 47(2008), 1 vom: 31. Dez., Seite 26-31 |w (DE-627)NLEJ248235222 |w (DE-600)1492732-9 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2008 |g number:1 |g day:31 |g month:12 |g pages:26-31 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1515/CCLM.2009.008 |z Deutschlandweit zugänglich |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DGR | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2008 |e 1 |b 31 |c 12 |h 26-31 |g 6 | ||
| matchkey_str |
article:14374331:2008----::yrrebsdeliecasyodtcinfkr1ncpcplmrhsshto |
|---|---|
| hierarchy_sort_str |
2008 |
| publishDate |
2008 |
| allfields |
10.1515/CCLM.2009.008 doi artikel_Grundlieferung.pp (DE-627)NLEJ246726105 DE-627 ger DE-627 rakwb SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement Walter de Gruyter 2008 6 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ©2009 by Walter de Gruyter Berlin New York Background: Polymorphisms in VKORC1 (vitamin K epoxide reductase complex subunit 1) and CYP2C9 (cytochrome P450 2C9) genes are considered the major genetic factors modulating warfarin dose requirement. As a result, a rapid and economic method for genotyping patients for predicting warfarin dose could be useful in clinical applications. Methods: In this study, we developed and validated a melting temperature (Tm)-shift genotyping assay for detection of VKORC1 C1173T and CYP2C9 A1075C polymorphisms by using SYBR Green-based multiplex allele-specific PCR and consequent melting curve analysis. In this Tm-shift genotyping assay, a GC-tail was incorporated into one of the two allele-specific primers to increase the melting temperature of PCR product, such that both alleles can be differentially detected simultaneously at their respective melting curve patterns. In total, 100 randomly selected samples of both VKORC1 and CYP2C9 genes from each genotype group determined by melting curve were validated by direct DNA sequencing and denaturing high-performance liquid chromatography (DHPLC) analysis. Results: There was 100% concordance between the results of DNA sequencing and Tm-shift genotyping, and 99% concordance between the results of DHPLC assay and Tm-shift genotyping. Conclusions: This allele-specific PCR assay is convenient, inexpensive and will be useful for VKORC1 and CYP2C9 genotyping in a clinic laboratory. Clin Chem Lab Med 2009;47:26–31. Walter de Gruyter Online Zeitschriften CYP2C9 real-time PCR Tm-shift genotyping VKORC1 warfarin Huang, Sheng-Wen oth Li, Qiang oth Zhu, Sheng-Yuan oth Li, Liang oth Xiong, Fu oth Jia, Yan-Kai oth Xu, Xiang-Min oth Enthalten in Clinical chemistry and laboratory medicine Berlin [u.a.] : De Gruyter, 1998 47(2008), 1 vom: 31. Dez., Seite 26-31 (DE-627)NLEJ248235222 (DE-600)1492732-9 1437-4331 nnns volume:47 year:2008 number:1 day:31 month:12 pages:26-31 extent:6 https://doi.org/10.1515/CCLM.2009.008 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 47 2008 1 31 12 26-31 6 |
| spelling |
10.1515/CCLM.2009.008 doi artikel_Grundlieferung.pp (DE-627)NLEJ246726105 DE-627 ger DE-627 rakwb SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement Walter de Gruyter 2008 6 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ©2009 by Walter de Gruyter Berlin New York Background: Polymorphisms in VKORC1 (vitamin K epoxide reductase complex subunit 1) and CYP2C9 (cytochrome P450 2C9) genes are considered the major genetic factors modulating warfarin dose requirement. As a result, a rapid and economic method for genotyping patients for predicting warfarin dose could be useful in clinical applications. Methods: In this study, we developed and validated a melting temperature (Tm)-shift genotyping assay for detection of VKORC1 C1173T and CYP2C9 A1075C polymorphisms by using SYBR Green-based multiplex allele-specific PCR and consequent melting curve analysis. In this Tm-shift genotyping assay, a GC-tail was incorporated into one of the two allele-specific primers to increase the melting temperature of PCR product, such that both alleles can be differentially detected simultaneously at their respective melting curve patterns. In total, 100 randomly selected samples of both VKORC1 and CYP2C9 genes from each genotype group determined by melting curve were validated by direct DNA sequencing and denaturing high-performance liquid chromatography (DHPLC) analysis. Results: There was 100% concordance between the results of DNA sequencing and Tm-shift genotyping, and 99% concordance between the results of DHPLC assay and Tm-shift genotyping. Conclusions: This allele-specific PCR assay is convenient, inexpensive and will be useful for VKORC1 and CYP2C9 genotyping in a clinic laboratory. Clin Chem Lab Med 2009;47:26–31. Walter de Gruyter Online Zeitschriften CYP2C9 real-time PCR Tm-shift genotyping VKORC1 warfarin Huang, Sheng-Wen oth Li, Qiang oth Zhu, Sheng-Yuan oth Li, Liang oth Xiong, Fu oth Jia, Yan-Kai oth Xu, Xiang-Min oth Enthalten in Clinical chemistry and laboratory medicine Berlin [u.a.] : De Gruyter, 1998 47(2008), 1 vom: 31. Dez., Seite 26-31 (DE-627)NLEJ248235222 (DE-600)1492732-9 1437-4331 nnns volume:47 year:2008 number:1 day:31 month:12 pages:26-31 extent:6 https://doi.org/10.1515/CCLM.2009.008 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 47 2008 1 31 12 26-31 6 |
| allfields_unstemmed |
10.1515/CCLM.2009.008 doi artikel_Grundlieferung.pp (DE-627)NLEJ246726105 DE-627 ger DE-627 rakwb SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement Walter de Gruyter 2008 6 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ©2009 by Walter de Gruyter Berlin New York Background: Polymorphisms in VKORC1 (vitamin K epoxide reductase complex subunit 1) and CYP2C9 (cytochrome P450 2C9) genes are considered the major genetic factors modulating warfarin dose requirement. As a result, a rapid and economic method for genotyping patients for predicting warfarin dose could be useful in clinical applications. Methods: In this study, we developed and validated a melting temperature (Tm)-shift genotyping assay for detection of VKORC1 C1173T and CYP2C9 A1075C polymorphisms by using SYBR Green-based multiplex allele-specific PCR and consequent melting curve analysis. In this Tm-shift genotyping assay, a GC-tail was incorporated into one of the two allele-specific primers to increase the melting temperature of PCR product, such that both alleles can be differentially detected simultaneously at their respective melting curve patterns. In total, 100 randomly selected samples of both VKORC1 and CYP2C9 genes from each genotype group determined by melting curve were validated by direct DNA sequencing and denaturing high-performance liquid chromatography (DHPLC) analysis. Results: There was 100% concordance between the results of DNA sequencing and Tm-shift genotyping, and 99% concordance between the results of DHPLC assay and Tm-shift genotyping. Conclusions: This allele-specific PCR assay is convenient, inexpensive and will be useful for VKORC1 and CYP2C9 genotyping in a clinic laboratory. Clin Chem Lab Med 2009;47:26–31. Walter de Gruyter Online Zeitschriften CYP2C9 real-time PCR Tm-shift genotyping VKORC1 warfarin Huang, Sheng-Wen oth Li, Qiang oth Zhu, Sheng-Yuan oth Li, Liang oth Xiong, Fu oth Jia, Yan-Kai oth Xu, Xiang-Min oth Enthalten in Clinical chemistry and laboratory medicine Berlin [u.a.] : De Gruyter, 1998 47(2008), 1 vom: 31. Dez., Seite 26-31 (DE-627)NLEJ248235222 (DE-600)1492732-9 1437-4331 nnns volume:47 year:2008 number:1 day:31 month:12 pages:26-31 extent:6 https://doi.org/10.1515/CCLM.2009.008 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 47 2008 1 31 12 26-31 6 |
| allfieldsGer |
10.1515/CCLM.2009.008 doi artikel_Grundlieferung.pp (DE-627)NLEJ246726105 DE-627 ger DE-627 rakwb SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement Walter de Gruyter 2008 6 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ©2009 by Walter de Gruyter Berlin New York Background: Polymorphisms in VKORC1 (vitamin K epoxide reductase complex subunit 1) and CYP2C9 (cytochrome P450 2C9) genes are considered the major genetic factors modulating warfarin dose requirement. As a result, a rapid and economic method for genotyping patients for predicting warfarin dose could be useful in clinical applications. Methods: In this study, we developed and validated a melting temperature (Tm)-shift genotyping assay for detection of VKORC1 C1173T and CYP2C9 A1075C polymorphisms by using SYBR Green-based multiplex allele-specific PCR and consequent melting curve analysis. In this Tm-shift genotyping assay, a GC-tail was incorporated into one of the two allele-specific primers to increase the melting temperature of PCR product, such that both alleles can be differentially detected simultaneously at their respective melting curve patterns. In total, 100 randomly selected samples of both VKORC1 and CYP2C9 genes from each genotype group determined by melting curve were validated by direct DNA sequencing and denaturing high-performance liquid chromatography (DHPLC) analysis. Results: There was 100% concordance between the results of DNA sequencing and Tm-shift genotyping, and 99% concordance between the results of DHPLC assay and Tm-shift genotyping. Conclusions: This allele-specific PCR assay is convenient, inexpensive and will be useful for VKORC1 and CYP2C9 genotyping in a clinic laboratory. Clin Chem Lab Med 2009;47:26–31. Walter de Gruyter Online Zeitschriften CYP2C9 real-time PCR Tm-shift genotyping VKORC1 warfarin Huang, Sheng-Wen oth Li, Qiang oth Zhu, Sheng-Yuan oth Li, Liang oth Xiong, Fu oth Jia, Yan-Kai oth Xu, Xiang-Min oth Enthalten in Clinical chemistry and laboratory medicine Berlin [u.a.] : De Gruyter, 1998 47(2008), 1 vom: 31. Dez., Seite 26-31 (DE-627)NLEJ248235222 (DE-600)1492732-9 1437-4331 nnns volume:47 year:2008 number:1 day:31 month:12 pages:26-31 extent:6 https://doi.org/10.1515/CCLM.2009.008 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 47 2008 1 31 12 26-31 6 |
| allfieldsSound |
10.1515/CCLM.2009.008 doi artikel_Grundlieferung.pp (DE-627)NLEJ246726105 DE-627 ger DE-627 rakwb SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement Walter de Gruyter 2008 6 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ©2009 by Walter de Gruyter Berlin New York Background: Polymorphisms in VKORC1 (vitamin K epoxide reductase complex subunit 1) and CYP2C9 (cytochrome P450 2C9) genes are considered the major genetic factors modulating warfarin dose requirement. As a result, a rapid and economic method for genotyping patients for predicting warfarin dose could be useful in clinical applications. Methods: In this study, we developed and validated a melting temperature (Tm)-shift genotyping assay for detection of VKORC1 C1173T and CYP2C9 A1075C polymorphisms by using SYBR Green-based multiplex allele-specific PCR and consequent melting curve analysis. In this Tm-shift genotyping assay, a GC-tail was incorporated into one of the two allele-specific primers to increase the melting temperature of PCR product, such that both alleles can be differentially detected simultaneously at their respective melting curve patterns. In total, 100 randomly selected samples of both VKORC1 and CYP2C9 genes from each genotype group determined by melting curve were validated by direct DNA sequencing and denaturing high-performance liquid chromatography (DHPLC) analysis. Results: There was 100% concordance between the results of DNA sequencing and Tm-shift genotyping, and 99% concordance between the results of DHPLC assay and Tm-shift genotyping. Conclusions: This allele-specific PCR assay is convenient, inexpensive and will be useful for VKORC1 and CYP2C9 genotyping in a clinic laboratory. Clin Chem Lab Med 2009;47:26–31. Walter de Gruyter Online Zeitschriften CYP2C9 real-time PCR Tm-shift genotyping VKORC1 warfarin Huang, Sheng-Wen oth Li, Qiang oth Zhu, Sheng-Yuan oth Li, Liang oth Xiong, Fu oth Jia, Yan-Kai oth Xu, Xiang-Min oth Enthalten in Clinical chemistry and laboratory medicine Berlin [u.a.] : De Gruyter, 1998 47(2008), 1 vom: 31. Dez., Seite 26-31 (DE-627)NLEJ248235222 (DE-600)1492732-9 1437-4331 nnns volume:47 year:2008 number:1 day:31 month:12 pages:26-31 extent:6 https://doi.org/10.1515/CCLM.2009.008 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 47 2008 1 31 12 26-31 6 |
| source |
Enthalten in Clinical chemistry and laboratory medicine 47(2008), 1 vom: 31. Dez., Seite 26-31 volume:47 year:2008 number:1 day:31 month:12 pages:26-31 extent:6 |
| sourceStr |
Enthalten in Clinical chemistry and laboratory medicine 47(2008), 1 vom: 31. Dez., Seite 26-31 volume:47 year:2008 number:1 day:31 month:12 pages:26-31 extent:6 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
CYP2C9 real-time PCR Tm-shift genotyping VKORC1 warfarin |
| isfreeaccess_bool |
false |
| container_title |
Clinical chemistry and laboratory medicine |
| authorswithroles_txt_mv |
Huang, Sheng-Wen @@oth@@ Li, Qiang @@oth@@ Zhu, Sheng-Yuan @@oth@@ Li, Liang @@oth@@ Xiong, Fu @@oth@@ Jia, Yan-Kai @@oth@@ Xu, Xiang-Min @@oth@@ |
| publishDateDaySort_date |
2008-12-31T00:00:00Z |
| hierarchy_top_id |
NLEJ248235222 |
| id |
NLEJ246726105 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ246726105</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506100904.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220814s2008 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/CCLM.2009.008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">artikel_Grundlieferung.pp</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ246726105</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="b">Walter de Gruyter</subfield><subfield code="c">2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">©2009 by Walter de Gruyter Berlin New York</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Polymorphisms in VKORC1 (vitamin K epoxide reductase complex subunit 1) and CYP2C9 (cytochrome P450 2C9) genes are considered the major genetic factors modulating warfarin dose requirement. As a result, a rapid and economic method for genotyping patients for predicting warfarin dose could be useful in clinical applications. Methods: In this study, we developed and validated a melting temperature (Tm)-shift genotyping assay for detection of VKORC1 C1173T and CYP2C9 A1075C polymorphisms by using SYBR Green-based multiplex allele-specific PCR and consequent melting curve analysis. In this Tm-shift genotyping assay, a GC-tail was incorporated into one of the two allele-specific primers to increase the melting temperature of PCR product, such that both alleles can be differentially detected simultaneously at their respective melting curve patterns. In total, 100 randomly selected samples of both VKORC1 and CYP2C9 genes from each genotype group determined by melting curve were validated by direct DNA sequencing and denaturing high-performance liquid chromatography (DHPLC) analysis. Results: There was 100% concordance between the results of DNA sequencing and Tm-shift genotyping, and 99% concordance between the results of DHPLC assay and Tm-shift genotyping. Conclusions: This allele-specific PCR assay is convenient, inexpensive and will be useful for VKORC1 and CYP2C9 genotyping in a clinic laboratory. Clin Chem Lab Med 2009;47:26–31.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Walter de Gruyter Online Zeitschriften</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CYP2C9</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">real-time PCR</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tm-shift genotyping</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">VKORC1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">warfarin</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huang, Sheng-Wen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Qiang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhu, Sheng-Yuan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Liang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xiong, Fu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jia, Yan-Kai</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xu, Xiang-Min</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical chemistry and laboratory medicine</subfield><subfield code="d">Berlin [u.a.] : De Gruyter, 1998</subfield><subfield code="g">47(2008), 1 vom: 31. Dez., Seite 26-31</subfield><subfield code="w">(DE-627)NLEJ248235222</subfield><subfield code="w">(DE-600)1492732-9</subfield><subfield code="x">1437-4331</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:47</subfield><subfield code="g">year:2008</subfield><subfield code="g">number:1</subfield><subfield code="g">day:31</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:26-31</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/CCLM.2009.008</subfield><subfield code="z">Deutschlandweit zugänglich</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DGR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">47</subfield><subfield code="j">2008</subfield><subfield code="e">1</subfield><subfield code="b">31</subfield><subfield code="c">12</subfield><subfield code="h">26-31</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| series2 |
Walter de Gruyter Online Zeitschriften |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ248235222 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1437-4331 |
| topic_title |
SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement CYP2C9 real-time PCR Tm-shift genotyping VKORC1 warfarin |
| publisher |
Walter de Gruyter |
| publisherStr |
Walter de Gruyter |
| topic |
misc CYP2C9 misc real-time PCR misc Tm-shift genotyping misc VKORC1 misc warfarin |
| spellingShingle |
misc CYP2C9 misc real-time PCR misc Tm-shift genotyping misc VKORC1 misc warfarin SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement |
| topic_unstemmed |
misc CYP2C9 misc real-time PCR misc Tm-shift genotyping misc VKORC1 misc warfarin |
| topic_browse |
misc CYP2C9 misc real-time PCR misc Tm-shift genotyping misc VKORC1 misc warfarin |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| author2_variant |
s w h swh q l ql s y z syz l l ll f x fx y k j ykj x m x xmx |
| hierarchy_parent_title |
Clinical chemistry and laboratory medicine |
| hierarchy_parent_id |
NLEJ248235222 |
| hierarchy_top_title |
Clinical chemistry and laboratory medicine |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ248235222 (DE-600)1492732-9 |
| title |
SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement |
| ctrlnum |
(DE-627)NLEJ246726105 |
| title_full |
SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement |
| journal |
Clinical chemistry and laboratory medicine |
| journalStr |
Clinical chemistry and laboratory medicine |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2008 |
| contenttype_str_mv |
txt |
| container_start_page |
26 |
| container_volume |
47 |
| physical |
6 |
| format_se |
Elektronische Aufsätze |
| doi_str_mv |
10.1515/CCLM.2009.008 |
| title_sort |
sybr green-based real-time pcr assay for detection of vkorc1 and cyp2c9 polymorphisms that modulate warfarin dose requirement |
| title_auth |
SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement |
| abstract |
Background: Polymorphisms in VKORC1 (vitamin K epoxide reductase complex subunit 1) and CYP2C9 (cytochrome P450 2C9) genes are considered the major genetic factors modulating warfarin dose requirement. As a result, a rapid and economic method for genotyping patients for predicting warfarin dose could be useful in clinical applications. Methods: In this study, we developed and validated a melting temperature (Tm)-shift genotyping assay for detection of VKORC1 C1173T and CYP2C9 A1075C polymorphisms by using SYBR Green-based multiplex allele-specific PCR and consequent melting curve analysis. In this Tm-shift genotyping assay, a GC-tail was incorporated into one of the two allele-specific primers to increase the melting temperature of PCR product, such that both alleles can be differentially detected simultaneously at their respective melting curve patterns. In total, 100 randomly selected samples of both VKORC1 and CYP2C9 genes from each genotype group determined by melting curve were validated by direct DNA sequencing and denaturing high-performance liquid chromatography (DHPLC) analysis. Results: There was 100% concordance between the results of DNA sequencing and Tm-shift genotyping, and 99% concordance between the results of DHPLC assay and Tm-shift genotyping. Conclusions: This allele-specific PCR assay is convenient, inexpensive and will be useful for VKORC1 and CYP2C9 genotyping in a clinic laboratory. Clin Chem Lab Med 2009;47:26–31. ©2009 by Walter de Gruyter Berlin New York |
| abstractGer |
Background: Polymorphisms in VKORC1 (vitamin K epoxide reductase complex subunit 1) and CYP2C9 (cytochrome P450 2C9) genes are considered the major genetic factors modulating warfarin dose requirement. As a result, a rapid and economic method for genotyping patients for predicting warfarin dose could be useful in clinical applications. Methods: In this study, we developed and validated a melting temperature (Tm)-shift genotyping assay for detection of VKORC1 C1173T and CYP2C9 A1075C polymorphisms by using SYBR Green-based multiplex allele-specific PCR and consequent melting curve analysis. In this Tm-shift genotyping assay, a GC-tail was incorporated into one of the two allele-specific primers to increase the melting temperature of PCR product, such that both alleles can be differentially detected simultaneously at their respective melting curve patterns. In total, 100 randomly selected samples of both VKORC1 and CYP2C9 genes from each genotype group determined by melting curve were validated by direct DNA sequencing and denaturing high-performance liquid chromatography (DHPLC) analysis. Results: There was 100% concordance between the results of DNA sequencing and Tm-shift genotyping, and 99% concordance between the results of DHPLC assay and Tm-shift genotyping. Conclusions: This allele-specific PCR assay is convenient, inexpensive and will be useful for VKORC1 and CYP2C9 genotyping in a clinic laboratory. Clin Chem Lab Med 2009;47:26–31. ©2009 by Walter de Gruyter Berlin New York |
| abstract_unstemmed |
Background: Polymorphisms in VKORC1 (vitamin K epoxide reductase complex subunit 1) and CYP2C9 (cytochrome P450 2C9) genes are considered the major genetic factors modulating warfarin dose requirement. As a result, a rapid and economic method for genotyping patients for predicting warfarin dose could be useful in clinical applications. Methods: In this study, we developed and validated a melting temperature (Tm)-shift genotyping assay for detection of VKORC1 C1173T and CYP2C9 A1075C polymorphisms by using SYBR Green-based multiplex allele-specific PCR and consequent melting curve analysis. In this Tm-shift genotyping assay, a GC-tail was incorporated into one of the two allele-specific primers to increase the melting temperature of PCR product, such that both alleles can be differentially detected simultaneously at their respective melting curve patterns. In total, 100 randomly selected samples of both VKORC1 and CYP2C9 genes from each genotype group determined by melting curve were validated by direct DNA sequencing and denaturing high-performance liquid chromatography (DHPLC) analysis. Results: There was 100% concordance between the results of DNA sequencing and Tm-shift genotyping, and 99% concordance between the results of DHPLC assay and Tm-shift genotyping. Conclusions: This allele-specific PCR assay is convenient, inexpensive and will be useful for VKORC1 and CYP2C9 genotyping in a clinic laboratory. Clin Chem Lab Med 2009;47:26–31. ©2009 by Walter de Gruyter Berlin New York |
| collection_details |
GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE |
| container_issue |
1 |
| title_short |
SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement |
| url |
https://doi.org/10.1515/CCLM.2009.008 |
| remote_bool |
true |
| author2 |
Huang, Sheng-Wen Li, Qiang Zhu, Sheng-Yuan Li, Liang Xiong, Fu Jia, Yan-Kai Xu, Xiang-Min |
| author2Str |
Huang, Sheng-Wen Li, Qiang Zhu, Sheng-Yuan Li, Liang Xiong, Fu Jia, Yan-Kai Xu, Xiang-Min |
| ppnlink |
NLEJ248235222 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1515/CCLM.2009.008 |
| up_date |
2024-07-06T09:11:51.455Z |
| _version_ |
1803820320902086657 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ246726105</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506100904.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220814s2008 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/CCLM.2009.008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">artikel_Grundlieferung.pp</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ246726105</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="b">Walter de Gruyter</subfield><subfield code="c">2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">©2009 by Walter de Gruyter Berlin New York</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Polymorphisms in VKORC1 (vitamin K epoxide reductase complex subunit 1) and CYP2C9 (cytochrome P450 2C9) genes are considered the major genetic factors modulating warfarin dose requirement. As a result, a rapid and economic method for genotyping patients for predicting warfarin dose could be useful in clinical applications. Methods: In this study, we developed and validated a melting temperature (Tm)-shift genotyping assay for detection of VKORC1 C1173T and CYP2C9 A1075C polymorphisms by using SYBR Green-based multiplex allele-specific PCR and consequent melting curve analysis. In this Tm-shift genotyping assay, a GC-tail was incorporated into one of the two allele-specific primers to increase the melting temperature of PCR product, such that both alleles can be differentially detected simultaneously at their respective melting curve patterns. In total, 100 randomly selected samples of both VKORC1 and CYP2C9 genes from each genotype group determined by melting curve were validated by direct DNA sequencing and denaturing high-performance liquid chromatography (DHPLC) analysis. Results: There was 100% concordance between the results of DNA sequencing and Tm-shift genotyping, and 99% concordance between the results of DHPLC assay and Tm-shift genotyping. Conclusions: This allele-specific PCR assay is convenient, inexpensive and will be useful for VKORC1 and CYP2C9 genotyping in a clinic laboratory. Clin Chem Lab Med 2009;47:26–31.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Walter de Gruyter Online Zeitschriften</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CYP2C9</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">real-time PCR</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tm-shift genotyping</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">VKORC1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">warfarin</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huang, Sheng-Wen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Qiang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhu, Sheng-Yuan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Liang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xiong, Fu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jia, Yan-Kai</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xu, Xiang-Min</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical chemistry and laboratory medicine</subfield><subfield code="d">Berlin [u.a.] : De Gruyter, 1998</subfield><subfield code="g">47(2008), 1 vom: 31. Dez., Seite 26-31</subfield><subfield code="w">(DE-627)NLEJ248235222</subfield><subfield code="w">(DE-600)1492732-9</subfield><subfield code="x">1437-4331</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:47</subfield><subfield code="g">year:2008</subfield><subfield code="g">number:1</subfield><subfield code="g">day:31</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:26-31</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/CCLM.2009.008</subfield><subfield code="z">Deutschlandweit zugänglich</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DGR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">47</subfield><subfield code="j">2008</subfield><subfield code="e">1</subfield><subfield code="b">31</subfield><subfield code="c">12</subfield><subfield code="h">26-31</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| score |
7.398514 |